Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Director Rebecca B. Robertson sold 500 shares of the firm’s stock in a transaction that occurred on Wednesday, June 9th. The stock was sold at an average price of $90.00, for a total transaction of $45,000.00. Following the completion of the transaction, the director now directly owns 2,392 shares in the company, valued at approximately $215,280. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Shares of Tandem Diabetes Care stock traded up $3.39 on Thursday, hitting $91.35. 486,166 shares of the company traded hands, compared to its average volume of 733,471. The firm has a market cap of $5.72 billion, a PE ratio of -191.22 and a beta of 0.19. The company has a quick ratio of 5.75, a current ratio of 6.40 and a debt-to-equity ratio of 0.89. Tandem Diabetes Care, Inc. has a 52 week low of $76.19 and a 52 week high of $123.74. The company’s 50-day moving average price is $87.31.
Tandem Diabetes Care (NASDAQ:TNDM) last released its quarterly earnings data on Wednesday, May 5th. The medical device company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.08. The firm had revenue of $141.04 million for the quarter, compared to analysts’ expectations of $122.66 million. Tandem Diabetes Care had a negative net margin of 4.53% and a negative return on equity of 1.12%. As a group, research analysts anticipate that Tandem Diabetes Care, Inc. will post 0.06 earnings per share for the current year.
A number of equities analysts recently issued reports on TNDM shares. Lake Street Capital raised their price objective on shares of Tandem Diabetes Care from $137.00 to $150.00 and gave the stock a “buy” rating in a report on Thursday, February 25th. Zacks Investment Research downgraded shares of Tandem Diabetes Care from a “buy” rating to a “hold” rating and set a $101.00 price objective on the stock. in a report on Monday, March 1st. Barclays started coverage on shares of Tandem Diabetes Care in a report on Monday, May 24th. They issued an “underweight” rating and a $90.00 price objective on the stock. Oppenheimer raised their price objective on shares of Tandem Diabetes Care from $130.00 to $135.00 in a report on Thursday, May 6th. Finally, SVB Leerink lifted their price target on shares of Tandem Diabetes Care from $95.00 to $102.00 and gave the company a “market perform” rating in a report on Thursday, May 6th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and nine have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $117.50.
About Tandem Diabetes Care
Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.
Recommended Story: Overbought
Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.